Who is sponsoring NCT04862247?

NCT04862247 is sponsored by University of Louisville.

What drugs are being tested in NCT04862247?

Interventions in NCT04862247: Imaginal Exposure Condition, Writing and Thinking Condition.

What condition does NCT04862247 study?

NCT04862247 studies Eating Disorders, Anorexia Nervosa, Bulimia Nervosa, Anorexia Nervosa, Atypical, Other Specified Feeding or Eating Disorder.

Is NCT04862247 still recruiting?

NCT04862247 is currently completed. Last updated 30 March 2025.

Last reviewed 2025-03-30 · How we verify

NCT04862247: ORP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Online Relapse Prevention Study

Completed NA Last updated 30 March 2025

What this trial tests

NA trial testing Imaginal Exposure Condition in Eating Disorders in 130 participants. Completed in 1 February 2025.

Timeline

4 June 2021

Primary endpoint
1 February 2025

1 February 2025

Quick facts

Lead sponsor	University of Louisville
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	130
Start date	4 June 2021
Primary completion	1 February 2025
Estimated completion	1 February 2025
Sites	1 location across United States

Drugs / interventions tested

Imaginal Exposure Condition
Writing and Thinking Condition

Conditions studied

Eating Disorders — all drugs for Eating Disorders →
Anorexia Nervosa — all drugs for Anorexia Nervosa →
Bulimia Nervosa — all drugs for Bulimia Nervosa →
Anorexia Nervosa, Atypical — all drugs for Anorexia Nervosa, Atypical →

Sponsor

University of Louisville

Who can join

Adults 18 to 65, any sex, with Eating Disorders or Anorexia Nervosa. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to collect preliminary data on the feasibility and acceptability of the randomization of two relapse-prevention treatment conditions after discharge from intensive eating disorder (ED) treatment: an imaginal exposure therapy and a writing and thinking intervention. The second aim to test for (a) differences between the two treatments for the prevention of relapse and (b) preliminary change on clinical ED outcomes (e.g., ED symptoms, fears). The investigators further aim to examine the two treatments target fear extinction and if fear extinction is associated with ED outcomes. The investigators also plan to test if baseline differences in fear conditioning relate to change in ED outcomes across treatment.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Comparisons between atypical anorexia nervosa and anorexia nervosa: Psychological and comorbidity patterns.
Fitterman-Harris HF, Han Y, Osborn KD, Faulkner LM, et al · · 2024 · cited 18× · PMID 38288579 · DOI 10.1002/eat.24147
A pilot randomized control trial of online exposure for eating disorders and mechanisms of change delivered after discharge from intensive eating disorder care: A registered report.
Levinson CA, Ralph-Nearman C, Brown ML, Gardner T, et al · · 2021 · cited 6× · PMID 34480773 · DOI 10.1002/eat.23603

Verify or expand the search:

Other recruiting trials for Eating Disorders

Currently open trials in the same condition.

NCT07237607 — Developing an Artificial Intelligence (AI) Chatbot for Adolescents and Young Adults With Eating Disorders · NA · recruiting
NCT07295197 — Oral Indicators for ED Screening · recruiting
NCT07082777 — Recovery in Telling Life Stories · NA · recruiting
NCT07042672 — Behavioral Therapy and GLP-1 Analogue Effects on Binge Eating, Weight, and Coping in Obesity · recruiting
NCT07017322 — Non-invasive Cranial Electrical Stimulation for Mealtime Anxiety in Adults With Eating Disorders · NA · recruiting

Other University of Louisville trials

Trials by the same sponsor.

NCT07219888 — Comparison of Suzetrigine and Oxycodone for Postoperative Pain After Primary Total Knee Arthroplasty · Phase 4 · not yet recruiting
NCT07044726 — Betadine vs Sterile Water for Periurethral Preparation · Phase 4 · not yet recruiting
NCT06489106 — Noninvasive Spinal Stimulation to Restore Hand Function in Children With Spinal Cord Injury · NA · enrolling by invitation
NCT06883513 — Osteopathic Manipulative Therapy Effects on Post-Acute Sequelae of COVID-19 (PASC) or Long COVID · NA · recruiting
NCT05920720 — Self-Guided Personalized Treatment for Women · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04862247 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Louisville
Last refreshed: 30 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04862247.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing